All In Biotech

Drug Trial Radar · NCT00002798

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

Last checked: Nov 20, 2026Latest source record: Jan 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

880

Actual

Start

Aug 1996

Primary completion

Sep 2006

Sponsor

Sponsor type
NIH
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome

Conditions

  • Childhood Acute Erythroleukemia (M6)
  • Childhood Acute Megakaryocytic Leukemia (M7)
  • Childhood Acute Monoblastic Leukemia (M5a)
  • Childhood Acute Monocytic Leukemia (M5b)
  • Childhood Acute Myeloblastic Leukemia With Maturation (M2)
  • Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
  • Childhood Acute Myelomonocytic Leukemia (M4)
  • Childhood Myelodysplastic Syndromes
  • Chronic Myelomonocytic Leukemia
  • de Novo Myelodysplastic Syndromes
  • Refractory Anemia
  • Refractory Anemia With Excess Blasts
  • Refractory Anemia With Excess Blasts in Transformation
  • Refractory Anemia With Ringed Sideroblasts
  • Secondary Myelodysplastic Syndromes
  • Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Interventions

  • asparaginaseDrug

  • daunorubicin hydrochlorideDrug

  • fludarabine phosphateDrug

  • therapeutic hydrocortisoneDrug

  • allogeneic bone marrow transplantationProcedure

  • 3-dimensional conformal radiation therapyRadiation

  • filgrastimBiological

    Given SC

  • cytarabineDrug

    Given IV or IT

  • idarubicinDrug

    Given IV

  • dexamethasoneDrug

    Given PO

  • thioguanineDrug

    Given PO

  • etoposideDrug

    Given IV

  • methotrexateDrug

    Given IT

  • cyclophosphamideDrug

    Given IV

  • aldesleukinBiological

  • busulfanDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportions of patients achieving remission rate during induction therapyTime frame: Up to 42 days
  2. Proportion of patients dying or with residual disease during induction therapyTime frame: Up to 42 days
  3. Time to marrow recovery (induction phase)Time frame: Up to 42 days
  4. Frequency of toxicities, including infectious complications (induction phase)Time frame: Up to 42 days
  5. Marrow statusTime frame: At 14 days
  6. Percent of blastsTime frame: At the end of induction therapy
  7. Complete remission at the end of consolidation therapyTime frame: Up to 5 years
  8. Survival following consolidationTime frame: Up to 5 years
  9. Event-free survival following consolidationTime frame: Up to 5 years
  10. Overall survival (intensification)Time frame: Up to 5 years
  11. EFS (intensification)Time frame: Up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's Oncology Group

    Arcadia, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.